OCT 01, 2020 8:04 PM PDT

Antidepressants Treats Lazy Eye

WRITTEN BY: Nouran Amin

A study published in Current Biology revealed how a therapeutic used as an antidepressant and for managing pain could treat adult amblyopia, a vision disorder often referred to as the “lazy eye”. The therapeutic is subanesthetic ketamine which is known to evoke rapid and long-lasting effects for treating depression.

Learn more about adult amblyopia which is the result of the brain failing to process inputs from one eye versus the other.

"Our study, demonstrates how a single-dose of subanesthetic ketamine reactivates adult visual cortical plasticity and promotes functional recovery of visual acuity defects resulting from amblyopia," explained Xiangmin Xu, PhD, a professor of anatomy and neurobiology and director of the Center for Neural Circuit Mapping at the UCI School of Medicine.

The study showed how ketamine could control the nervous system and make structural changes in a process known as neural plasticity.

"Our research team showed that ketamine down-regulates NRG1 expression in PV inhibitory cells, resulting in sustained cortical disinhibition to enhance cortical plasticity in adult visual cortex," said Steven F. Grieco, PhD, a postdoctoral scholar in the Xu lab and lead author.

"Through this neural plasticity-based mechanism, ketamine mediated functional recovery from adult amblyopia." Xin Qiao, PhD, a postdoctoral staff in the Xu lab is a co-first author for the published paper.

The study confirmed that utilizing sustained treatments of ketamine reactivates adult cortical plasticity however, more research is needed.

Source: Science Daily

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JAN 20, 2021
Microbiology
Cannabis Compound Could Lead to New Class of Antibiotics
JAN 20, 2021
Cannabis Compound Could Lead to New Class of Antibiotics
For the first time, a synthetic version of a non-psychoactive molecule found in marijuana has been shown to kill pathoge ...
JAN 27, 2021
Drug Discovery & Development
Do Vaccines Work Against New Covid Variants?
JAN 27, 2021
Do Vaccines Work Against New Covid Variants?
The SARS-CoV-2 virus is mutating faster than scientists previously thought. As such, pharmaceutical companies are now sc ...
FEB 06, 2021
Cannabis Sciences
Cannabis Reduces Disruptive Behavior in 50% of Young People with Autism
FEB 06, 2021
Cannabis Reduces Disruptive Behavior in 50% of Young People with Autism
Current pharmacotherapies for disruptive behaviors among those with autism are relatively ineffective. Now though, resea ...
FEB 10, 2021
Drug Discovery & Development
Ketamine Reduces Suicidal Thoughts in Patients with Depression
FEB 10, 2021
Ketamine Reduces Suicidal Thoughts in Patients with Depression
Ketamine has been known for some time for its ability to tackle depression. Now, however, researchers have found that or ...
FEB 10, 2021
Cannabis Sciences
Cannabis Lowers Blood Pressure in Older Adults
FEB 10, 2021
Cannabis Lowers Blood Pressure in Older Adults
Researchers from Ben-Gurion University of the Negev (BGU) in Israel have found that medical cannabis may reduce blood pr ...
APR 14, 2021
Drug Discovery & Development
Anti-Aging Compound Improves Glucose Uptake
APR 14, 2021
Anti-Aging Compound Improves Glucose Uptake
According to new research at Washington University School of Medicine in St. Louis, a substance shown to counteract aspe ...
Loading Comments...